Susquehanna Fundamental Investments LLC Acquires New Shares in Denali Therapeutics Inc. (NASDAQ:DNLI)

Susquehanna Fundamental Investments LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 192,563 shares of the company's stock, valued at approximately $3,924,000. Susquehanna Fundamental Investments LLC owned 0.13% of Denali Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sterling Capital Management LLC lifted its position in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after buying an additional 1,516 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after acquiring an additional 885 shares during the last quarter. KBC Group NV boosted its position in shares of Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after purchasing an additional 2,731 shares during the period. AlphaQuest LLC increased its holdings in Denali Therapeutics by 177.1% in the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after purchasing an additional 4,449 shares during the last quarter. Finally, E Fund Management Co. Ltd. raised its position in Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group dropped their price objective on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. HC Wainwright lifted their target price on Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target on the stock. Robert W. Baird began coverage on shares of Denali Therapeutics in a report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price objective for the company. Finally, Bank of America cut their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Denali Therapeutics has an average rating of "Buy" and a consensus price target of $37.57.

Denali Therapeutics Stock Performance

Denali Therapeutics stock traded up $0.38 during midday trading on Friday, hitting $16.44. 1,118,564 shares of the company's stock were exchanged, compared to its average volume of 1,087,313. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of -5.96 and a beta of 1.49. Denali Therapeutics Inc. has a 12-month low of $10.57 and a 12-month high of $33.33. The firm's 50 day simple moving average is $14.51 and its 200 day simple moving average is $20.41.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. On average, equities research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.